ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,190.00
-200.00 (-5.90%)
At close: Jun 26, 2026
Market Cap291.16B -38.7%
Revenue (ttm)59.44M -91.6%
Net Income-28.54B
EPS-391.29
Shares Out 91.27M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume778,919
Open3,435.00
Previous Close3,390.00
Day's Range3,050.00 - 3,495.00
52-Week Range3,050.00 - 16,110.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About ImmuneOncia Therapeutics

ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, which is in Phase I a clinical trial for the treatment of solid cancers, su... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 424870
Full Company Profile

Financial Performance

In 2025, ImmuneOncia Therapeutics's revenue was 111.21 million, a decrease of -83.01% compared to the previous year's 654.54 million. Losses were -27.36 billion, 381.2% more than in 2024.

Financial Statements